FindTrial
Sign In

Efficacy of long-term, low dose macrolide therapy for asthma: a systematic review and meta-analysis

Efficacy of long-term, low dose macrolide therapy for asthma: a systematic review and meta-analysis - Efficacy of long-term, low dose macrolide therapy for asthma: a systematic review and meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000050824
Enrollment
Unknown
Registered
2023-04-17
Start date
2023-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

None listed

Sponsors

The Japanese Respiratory Society
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: According to Global Initiative for Asthma 2022, adult asthma outpatients will be included in the study. The literature to be included will be randomized controlled trials. Macrolides will include clarithromycin, troleandomycin, erythromycin, josamycin, azithromycin, and roxithromycin.

Exclusion criteria

Exclusion criteria: Pediatric patients under 18 years of old

Design outcomes

Primary

MeasureTime frame
Exacerbation requiring hospitalization—

Secondary

MeasureTime frame
Severe exacerbations (requiring ED visits or systemic steroids, or both), serious adverse events (including mortality), asthma symptoms (symptom scales, Asthma Control Questionnaire, Asthma quality of life (AQLQ) ), rescue medication (puffs/day), respiratory function (morning PEF, evening PEF, FEV1), bronchial hyperresponsiveness (BHR), and minimum oral corticosteroid dose.—

Countries

Japan

Contacts

Public ContactYosuke Fukuda

Showa University, School of Medicine Department of Medicine, Division of Respiratory Medicine and Allergology

y.f.0423@med.showa-u.ac.jp03-3784-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026